Eli Lilly's Liver Cancer Trial With Cyramza Fails To Meet Primary Endpoint

June 11, 2014 2:35 PM

4 0

Eli Lilly's Liver Cancer Trial With Cyramza Fails To Meet Primary Endpoint

Drugmaker Eli Lilly and Co. (LLY: Quote) Wednesday said Phase III trial of Cyramza or ramucirumab in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint. Overall survival, however, favored the Cyramza arm but was not statistically significant.

The primary endpoint of the trial was overall survival and key secondary endpoints include progression-free survival, overall response rate, time to progression and safety.

Read more

To category page

Loading...